A novel Bcl-x splice product, Bcl-xAK, triggers apoptosis in human melanoma cells without BH3 domain

Oncogene

Volumn 25, Issue 15, 2006, Pages 2160-2169

  Hossini, A M ^a   Geilen, C C ^a   Fecker, L F ^a   Daniel, P T ^a   Eberle, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Alternative splicing; Apoptosis; Bcl x; Chemotherapeutics; Melanoma

Indexed keywords

BCL X ATYPICAL KILLER PROTEIN; DOXORUBICIN; ETOPOSIDE; FAS ANTIBODY; GENE PRODUCT; PAMIDRONIC ACID; PROTEIN BCL X; TETRACYCLINE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOSOL; GENE EXPRESSION SYSTEM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; APOPTOSIS; BCL-X PROTEIN; CLONING, MOLECULAR; CYTOSOL; DOXYCYCLINE; HELA CELLS; HUMANS; MELANOMA; MITOCHONDRIA; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE HOMOLOGY, AMINO ACID; SKIN NEOPLASMS; SUBCELLULAR FRACTIONS;

EID: 33645730665     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209253     Document Type: Article

References (62)

1. Ban J, Eckhart L, Weninger W, Mildner M, Tschachler E. (1998). Biochem Biophys Res Commun 248: 147-152.
2. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B et al. (1995). Int J Cancer 60: 854-859.
3. Bean MA, Bloom BR, Herberman RB, Old LJ, Oettgen HF, Klein G et al. (1975). Cancer Res 35: 2902-2913.
4. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA et al. (1993). Cell 74: 597-608.
5. Borner C. (2003). Mol Immunol 39: 615-647.
6. Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S et al. (2000). Biochem Pharmacol 60: 1085-1089.
7. Bruggen J, Fogh J, Sorg C. (1981). J Cancer Res Clin Oncol 102: 141-152.
8. Cardone MH, Salvesen GS, Widmann C, Johnson G, Frisch SM. (1997). Cell 90: 315-323.
9. Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ. (1976). Proc Natl Acad Sci USA 73: 3278-3282.
10. Clarke MF, Apel IJ, Benedict MA, Eipers PG, Sumantran V, Gonzalez-Garcia M et al. (1995). Proc Natl Acad Sci USA 92: 11024-11028.
11. Daniel PT, Schulze-Osthoff K, Belka C, Guner D. (2003). Essays Biochem 39: 73-88.
12. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. (1997). Science 278: 687-689.
13. Diaz JL, Oltersdorf T, Horne W, McConnell M, Wilson G, Weeks S et al. (1997). J Biol Chem 272: 11350-11355.
14. Eberle J, Fecker LF, Bittner JU, Orfanos CE, Geilen CC. (2002). Br J Cancer 86: 1957-1962.
15. Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel PT, Orfanos CE et al. (2003). Oncogene 22: 9131-9141.
16. Eberle J, Weitmann S, Thieck O, Pech H, Paul M, Orfanos CE. (1999). J Invest Dermatol 112: 925-932.
17. Eskes R, Desagher S, Antonsson B, Martinou JC. (2000). Mol Cell Biol 20: 929-935.
18. Fecker LF, Eberle J, Orfanos CE, Geilen CC. (2002). J Invest Dermatol 118: 1019-1025.
19. Fults D, Pedone CA, Morse HG, Rose JW, McKay RD. (1992). J Neuropathol Exp Neurol 51: 272-280.
20. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H et al. (1973). J Natl Cancer Inst 51: 1417-1423.
21. Gillissen B, Essmann F, Graupner V, Starck L, Radetzki S, Dorken B et al. (2003). EMBO J 22: 3580-3590.
22. Gossen M, Bujard H. (1992). Proc Natl Acad Sci USA 89: 5547-5551.
23. Grad JM, Zeng XR, Boise LH. (2000). Curr Opin Oncol 12: 543-549.
24. Grillot DA, Gonzalez-Garcia M, Ekhterae D, Duan L, Inohara N, Ohta S et al. (1997). J Immunol 158: 4750-4757.
25. Gross A, McDonnell JM, Korsmeyer SJ. (1999). Genes Dev 13: 1899-1911.
26. Guo B, Godzik A, Reed JC. (2001). J Biol Chem 276: 2780-2785.
27. Hipp ML, Bauer G. (1997). Oncogene 15: 791-797.
28. Holzmann B, Lehmann JM, Ziegler-Heitbrock HW, Funke I, Riethmuller G, Johnson JP. (1988). Int J Cancer 41: 542-547.
29. Hossini AM, Eberle J, Fecker LF, Orfanos CE, Geilen CC. (2003a). FEBS Lett 553: 250-256.
30. Hossini AM, Eberle J, Fecker LF, Orfanos CE, Geilen CC. (2003b). Arch Dermatol Res 294: 499, abstract 153.
31. Hussein MR, Haemel AK, Wood GS. (2003). J Pathol 199: 275-288.
32. Jin KL, Graham SH, Mao XO, He X, Nagayama T, Simon RP et al. (2001). J Neurochem 77: 1508-1519.
33. Johnstone RW, Ruefli AA, Lowe SW. (2002). Cell 108: 153-164.
34. Kelekar A, Thompson CB. (1998). Trends Cell Biol 8: 324-330.
35. Kim MR, Lee JY, Park MT, Chun YJ, Jang YJ, Kang CM et al. (2001). FEBS Lett 505: 179-184.
36. Leech SH, Olie RA, Gautschi O, Simoes-Wust AP, Tschopp S, Haner R et al. (2000). Int J Cancer 86: 570-576.
37. Li H, Yuan J. (1999). Curr Opin Cell Biol 11: 261-266.
38. Liao SK, Dent PB, McCulloch PB. (1975). J Natl Cancer Inst 54: 1037-1044.
39. Lindenboim L, Yuan J, Stein R. (2000). Oncogene 19: 1783-1793.
40. Losonczi JA, Olejniczak ET, Betz SF, Harlan JE, Mack J, Fesik SW. (2000). Biochemistry 39: 11024-11033.
41. Marani M, Hancock D, Lopes R, Tenev T, Downward J, Lemoine NR. (2004). Oncogene 23: 2431-2441.
42. Matsuyama S, Schendel SL, Xie Z, Reed JC. (1998). J Biol Chem 213: 30995-31001.
43. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK et al. (2002). Cell 109: 707-718.
44. Mercatante DR, Bortner CD, Cidlowski JA, Kole R. (2001). J Biol Chem 276: 16411-16417.
45. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS et al. (1996). Nature 381: 335-341.
46. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. (1991). J Immunol Methods 139: 271-279.
47. Ogata Y, Takahashi M. (2003). Drug News Perspect 16: 446-452.
48. Oppermann M, Geilen CC, Fecker LF, Gillissen B, Daniel PT, Eberle J. (2005). Oncogene, Epub ahead of print, PMID. 16007125.
49. Osford SM, Dallman CL, Johnson PW, Ganesan A, Packham G. (2004). Curr Med Chem 11: 1031-1039.
50. Petros AM, Olejniczak ET, Fesik SW. (2004). Biochim Biophys Acta 1644: 83-94.
51. Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I et al. (2001). J Invest Dermatol 117: 333-340.
52. Reed JC. (1998). Oncogene 17: 3225-3236.
53. Renshaw SA, Dempsey CE, Barnes FA, Bagstaff SM, Dower SK, Bingle CD et al. (2004). J Biol Chem 279: 2846-2855.
54. Schendel SL, Xie Z, Montai MO, Matsuyama S, Montai M, Reed JC. (1997). Proc Natl Acad Sci USA 94: 5113-5118.
55. Scherer WF, Syverton JT, Gey GO. (1953). J Exp Med 97: 695-710.
56. Schmitt E, Paquet C, Beauchemin M, Bertrand R. (2004). Oncogene 23: 3915-3931.
57. Schwarz CS, Seyfried J, Evert BO, Klockgether T, Wullner U. (2002). Neuroreport 13: 2439-2442.
58. Shiraiwa N, Inohara N, Okada S, Yuzaki M, Shoji S, Ohta S. (1996). J Biol Chem 271: 13258-13265.
59. Vander Heiden MG, Thompson CB. (1999). Nat Cell Biol 1: E209-E216.
60. Yang E, Korsmeyer SJ. (1996). Blood 88: 386-401.
61. Yin XM, Oltvai ZN, Korsmeyer SJ. (1994). Nature 369: 321-323.
62. Zamzami N, Brenner C, Marzo I, Susin SA, Kroemer G. (1998). Oncogene 16: 2265-2282.